JP2017502068A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017502068A5 JP2017502068A5 JP2016545882A JP2016545882A JP2017502068A5 JP 2017502068 A5 JP2017502068 A5 JP 2017502068A5 JP 2016545882 A JP2016545882 A JP 2016545882A JP 2016545882 A JP2016545882 A JP 2016545882A JP 2017502068 A5 JP2017502068 A5 JP 2017502068A5
- Authority
- JP
- Japan
- Prior art keywords
- imidazo
- amino
- alkyl
- quinolin
- ethoxymethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 24
- 125000003342 alkenyl group Chemical group 0.000 claims description 21
- -1 - NH 2 Chemical group 0.000 claims description 16
- 125000003118 aryl group Chemical group 0.000 claims description 16
- 125000003545 alkoxy group Chemical group 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 13
- 239000001257 hydrogen Substances 0.000 claims description 13
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 13
- 125000001072 heteroaryl group Chemical group 0.000 claims description 12
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 125000000304 alkynyl group Chemical group 0.000 claims description 9
- 125000001188 haloalkyl group Chemical group 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 6
- 125000001424 substituent group Chemical group 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 125000005745 ethoxymethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])* 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 229940022353 herceptin Drugs 0.000 claims 5
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 5
- 229960000575 trastuzumab Drugs 0.000 claims 5
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 4
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- YZOQZEXYFLXNKA-UHFFFAOYSA-N n-[4-(4-amino-2-ethylimidazo[4,5-c]quinolin-1-yl)butyl]methanesulfonamide Chemical compound C1=CC=CC2=C(N(C(CC)=N3)CCCCNS(C)(=O)=O)C3=C(N)N=C21 YZOQZEXYFLXNKA-UHFFFAOYSA-N 0.000 claims 4
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 4
- 210000004881 tumor cell Anatomy 0.000 claims 4
- SVBZCXQPNPURIX-UHFFFAOYSA-N 1-(2-amino-2-methylpropyl)-2-(ethoxymethyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)N)C3=C(N)N=C21 SVBZCXQPNPURIX-UHFFFAOYSA-N 0.000 claims 3
- FNGOMDSFESDBEW-UHFFFAOYSA-N 1-(4-amino-2-ethyl-7-pyridin-4-ylimidazo[4,5-c]quinolin-1-yl)-2-methylpropan-2-ol Chemical compound C1=CC2=C3N(CC(C)(C)O)C(CC)=NC3=C(N)N=C2C=C1C1=CC=NC=C1 FNGOMDSFESDBEW-UHFFFAOYSA-N 0.000 claims 3
- RABCHZGIHKCQEP-UHFFFAOYSA-N 1-[2-[2-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-3-cyclohexylurea Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOCCNC(=O)NC1CCCCC1 RABCHZGIHKCQEP-UHFFFAOYSA-N 0.000 claims 3
- RKHPJMXDRRZPGD-UHFFFAOYSA-N 1-[4-(4-amino-2-butylimidazo[4,5-c][1,5]naphthyridin-1-yl)butyl]-3-butylurea Chemical compound C1=CC=NC2=C3N(CCCCNC(=O)NCCCC)C(CCCC)=NC3=C(N)N=C21 RKHPJMXDRRZPGD-UHFFFAOYSA-N 0.000 claims 3
- FHJATBIERQTCTN-UHFFFAOYSA-N 1-[4-amino-2-(ethylaminomethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol Chemical compound C1=CC=CC2=C(N(C(CNCC)=N3)CC(C)(C)O)C3=C(N)N=C21 FHJATBIERQTCTN-UHFFFAOYSA-N 0.000 claims 3
- DITHACKITKTCMN-UHFFFAOYSA-N 2-(ethoxymethyl)-1-[2-(3-phenylmethoxypropoxy)ethyl]imidazo[4,5-c]quinolin-4-amine Chemical compound CCOCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOCCCOCC1=CC=CC=C1 DITHACKITKTCMN-UHFFFAOYSA-N 0.000 claims 3
- HLPUJJZDRNYGNZ-UHFFFAOYSA-N 2-(ethoxymethyl)-1-n-propan-2-yl-6,7,8,9-tetrahydroimidazo[4,5-c]quinoline-1,4-diamine Chemical compound C1CCCC2=C(N(C(COCC)=N3)NC(C)C)C3=C(N)N=C21 HLPUJJZDRNYGNZ-UHFFFAOYSA-N 0.000 claims 3
- DXDGDCBZWVCDHG-UHFFFAOYSA-N 2-amino-n-[2-(4-amino-2-butylimidazo[4,5-c][1,5]naphthyridin-1-yl)ethyl]-4-methylpentanamide Chemical compound C1=CC=NC2=C(N(C(CCCC)=N3)CCNC(=O)C(N)CC(C)C)C3=C(N)N=C21 DXDGDCBZWVCDHG-UHFFFAOYSA-N 0.000 claims 3
- NFYMGJSUKCDVJR-UHFFFAOYSA-N 2-propyl-[1,3]thiazolo[4,5-c]quinolin-4-amine Chemical group C1=CC=CC2=C(SC(CCC)=N3)C3=C(N)N=C21 NFYMGJSUKCDVJR-UHFFFAOYSA-N 0.000 claims 3
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 3
- 125000003277 amino group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 229950003135 margetuximab Drugs 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 229960002087 pertuzumab Drugs 0.000 claims 3
- BIWKOBSVKIEQLD-UHFFFAOYSA-N 1-[1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-yl]-3-cyclopentylurea Chemical compound NC1=NC=2C=CC=CC2C2=C1N=C(N2CC(C)(C)NC(=O)NC2CCCC2)COCC BIWKOBSVKIEQLD-UHFFFAOYSA-N 0.000 claims 2
- QNOAFXQYZVGWMO-UHFFFAOYSA-N 1-[1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-yl]-3-propylurea Chemical compound NC1=NC=2C=CC=CC2C2=C1N=C(N2CC(C)(C)NC(=O)NCCC)COCC QNOAFXQYZVGWMO-UHFFFAOYSA-N 0.000 claims 2
- RLGNIXAVMDVPSM-UHFFFAOYSA-N 1-[4-(3,5-dichlorophenyl)sulfonylbutyl]-2-ethylimidazo[4,5-c]quinolin-4-amine Chemical compound CCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCCCS(=O)(=O)C1=CC(Cl)=CC(Cl)=C1 RLGNIXAVMDVPSM-UHFFFAOYSA-N 0.000 claims 2
- GRGBJCMHYKWROJ-UHFFFAOYSA-N 1-[4-(4-amino-2-butylimidazo[4,5-c][1,5]naphthyridin-1-yl)butyl]-3-cyclohexylurea Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=NC3=C2N1CCCCNC(=O)NC1CCCCC1 GRGBJCMHYKWROJ-UHFFFAOYSA-N 0.000 claims 2
- RXNTZIJLOZMJTM-UHFFFAOYSA-N 2-(2h-quinolin-1-yl)ethanol Chemical compound C1=CC=C2N(CCO)CC=CC2=C1 RXNTZIJLOZMJTM-UHFFFAOYSA-N 0.000 claims 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 claims 2
- HCLMCYDABWTVKQ-UHFFFAOYSA-N 3-[4-amino-2-(ethoxymethyl)-7-pyridin-3-ylimidazo[4,5-c]quinolin-1-yl]propane-1,2-diol Chemical compound C1=CC2=C3N(CC(O)CO)C(COCC)=NC3=C(N)N=C2C=C1C1=CC=CN=C1 HCLMCYDABWTVKQ-UHFFFAOYSA-N 0.000 claims 2
- WPCIWMJWVMQOBT-UHFFFAOYSA-N 4-[4-amino-2-(ethoxymethyl)-1-(2-hydroxy-2-methylpropyl)imidazo[4,5-c]quinolin-7-yl]-n-methoxy-n-methylbenzamide Chemical compound C1=CC2=C3N(CC(C)(C)O)C(COCC)=NC3=C(N)N=C2C=C1C1=CC=C(C(=O)N(C)OC)C=C1 WPCIWMJWVMQOBT-UHFFFAOYSA-N 0.000 claims 2
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 2
- 101100294115 Caenorhabditis elegans nhr-4 gene Proteins 0.000 claims 2
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims 2
- UDHPLJGOINSMFG-UHFFFAOYSA-N [4-[4-amino-1-[(2,2-dimethyl-1,3-dioxolan-4-yl)methyl]-2-(ethoxymethyl)imidazo[4,5-c]quinolin-7-yl]phenyl]methanol Chemical compound CCOCC1=NC2=C(N)N=C3C=C(C=4C=CC(CO)=CC=4)C=CC3=C2N1CC1COC(C)(C)O1 UDHPLJGOINSMFG-UHFFFAOYSA-N 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 229960002751 imiquimod Drugs 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims 2
- SBHDTQQLGBQXLR-UHFFFAOYSA-N n-[3-[4-amino-1-(2-hydroxy-2-methylpropyl)-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-7-yl]phenyl]methanesulfonamide Chemical compound C1=CC2=C3N(CC(C)(C)O)C(CCOC)=NC3=C(N)N=C2C=C1C1=CC=CC(NS(C)(=O)=O)=C1 SBHDTQQLGBQXLR-UHFFFAOYSA-N 0.000 claims 2
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical group C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 claims 2
- 229950010550 resiquimod Drugs 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000012453 solvate Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- ZLZKHTRPQRBTHF-UHFFFAOYSA-N 1-[2-[2-[4-amino-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]ethoxy]ethyl]-3-phenylurea Chemical compound COCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CCOCCNC(=O)NC1=CC=CC=C1 ZLZKHTRPQRBTHF-UHFFFAOYSA-N 0.000 claims 1
- GTUCHIHDDSGYMP-UHFFFAOYSA-N 1-[4-amino-2-(ethoxymethyl)-7-pyridin-3-ylimidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol Chemical compound C1=CC2=C3N(CC(C)(C)O)C(COCC)=NC3=C(N)N=C2C=C1C1=CC=CN=C1 GTUCHIHDDSGYMP-UHFFFAOYSA-N 0.000 claims 1
- QHPGZBNQBMJYAG-UHFFFAOYSA-N 1-[4-amino-2-(ethoxymethyl)-7-pyridin-4-ylimidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol Chemical compound C1=CC2=C3N(CC(C)(C)O)C(COCC)=NC3=C(N)N=C2C=C1C1=CC=NC=C1 QHPGZBNQBMJYAG-UHFFFAOYSA-N 0.000 claims 1
- NXRIDAMREUIFDQ-UHFFFAOYSA-N 1-[4-amino-7-[5-(hydroxymethyl)pyridin-3-yl]-2-(2-methoxyethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol Chemical compound C1=CC2=C3N(CC(C)(C)O)C(CCOC)=NC3=C(N)N=C2C=C1C1=CN=CC(CO)=C1 NXRIDAMREUIFDQ-UHFFFAOYSA-N 0.000 claims 1
- RFZSZPJGVHUALX-UHFFFAOYSA-N 2-butyl-1-(3-methylsulfonylpropyl)imidazo[4,5-c]quinolin-4-amine Chemical compound C1=CC=CC2=C(N(C(CCCC)=N3)CCCS(C)(=O)=O)C3=C(N)N=C21 RFZSZPJGVHUALX-UHFFFAOYSA-N 0.000 claims 1
- 102000003915 DNA Topoisomerases Human genes 0.000 claims 1
- 108090000323 DNA Topoisomerases Proteins 0.000 claims 1
- 101150029707 ERBB2 gene Proteins 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 229940122255 Microtubule inhibitor Drugs 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 239000004146 Propane-1,2-diol Substances 0.000 claims 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 claims 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000004414 alkyl thio group Chemical group 0.000 claims 1
- 239000002168 alkylating agent Substances 0.000 claims 1
- 229940100198 alkylating agent Drugs 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 230000002280 anti-androgenic effect Effects 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 239000000051 antiandrogen Substances 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 125000005110 aryl thio group Chemical group 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- 210000003679 cervix uteri Anatomy 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 210000004696 endometrium Anatomy 0.000 claims 1
- 210000003238 esophagus Anatomy 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 101150108262 gnrh1 gene Proteins 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 231100000782 microtubule inhibitor Toxicity 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- OOHUVTQQUWSOPZ-UHFFFAOYSA-N n-[1-[4-amino-2-(ethoxymethyl)imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-yl]-2-ethoxyacetamide Chemical compound C1=CC=CC2=C3N(CC(C)(C)NC(=O)COCC)C(COCC)=NC3=C(N)N=C21 OOHUVTQQUWSOPZ-UHFFFAOYSA-N 0.000 claims 1
- BQLBSBWCGKYXGM-UHFFFAOYSA-N n-[3-(4-amino-2-butylimidazo[4,5-c]quinolin-1-yl)-2,2-dimethylpropyl]benzamide Chemical compound CCCCC1=NC2=C(N)N=C3C=CC=CC3=C2N1CC(C)(C)CNC(=O)C1=CC=CC=C1 BQLBSBWCGKYXGM-UHFFFAOYSA-N 0.000 claims 1
- 210000003739 neck Anatomy 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 210000001672 ovary Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 229960004063 propylene glycol Drugs 0.000 claims 1
- 235000013772 propylene glycol Nutrition 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 210000000664 rectum Anatomy 0.000 claims 1
- 210000002784 stomach Anatomy 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 210000003932 urinary bladder Anatomy 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410011324.5 | 2014-01-10 | ||
| CN201410011324.5A CN104861067A (zh) | 2014-01-10 | 2014-01-10 | 用于免疫疗法的化合物和组合物 |
| CN201410011362.0A CN104861064A (zh) | 2014-01-10 | 2014-01-10 | 靶向表达egfr的肿瘤的化合物和组合物 |
| CN201410011262.8A CN104861063A (zh) | 2014-01-10 | 2014-01-10 | 靶向her2阳性肿瘤的化合物和组合物 |
| CN201410011262.8 | 2014-01-10 | ||
| CN201410011362.0 | 2014-01-10 | ||
| PCT/CN2015/070377 WO2015103987A1 (en) | 2014-01-10 | 2015-01-08 | Compounds and compositions for treating her2 positive tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017502068A JP2017502068A (ja) | 2017-01-19 |
| JP2017502068A5 true JP2017502068A5 (enExample) | 2018-02-15 |
Family
ID=53523554
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016545803A Expired - Fee Related JP6957154B2 (ja) | 2014-01-10 | 2015-01-08 | 免疫療法のための化合物及び組成物 |
| JP2016545882A Withdrawn JP2017502068A (ja) | 2014-01-10 | 2015-01-08 | Ｈｅｒ２陽性腫瘍を処置するための化合物及び組成物 |
| JP2016545802A Withdrawn JP2017503803A (ja) | 2014-01-10 | 2015-01-08 | Ｅｇｆｒ発現腫瘍を処置するための化合物及び組成物 |
| JP2020048941A Active JP7290332B2 (ja) | 2014-01-10 | 2020-03-19 | 免疫療法のための化合物及び組成物 |
| JP2022107558A Pending JP2022126880A (ja) | 2014-01-10 | 2022-07-04 | 免疫療法のための化合物及び組成物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016545803A Expired - Fee Related JP6957154B2 (ja) | 2014-01-10 | 2015-01-08 | 免疫療法のための化合物及び組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016545802A Withdrawn JP2017503803A (ja) | 2014-01-10 | 2015-01-08 | Ｅｇｆｒ発現腫瘍を処置するための化合物及び組成物 |
| JP2020048941A Active JP7290332B2 (ja) | 2014-01-10 | 2020-03-19 | 免疫療法のための化合物及び組成物 |
| JP2022107558A Pending JP2022126880A (ja) | 2014-01-10 | 2022-07-04 | 免疫療法のための化合物及び組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (11) | US20170028079A1 (enExample) |
| EP (4) | EP3092255A4 (enExample) |
| JP (5) | JP6957154B2 (enExample) |
| CN (6) | CN105899538A (enExample) |
| AU (3) | AU2015205755C1 (enExample) |
| CA (3) | CA2936375A1 (enExample) |
| DK (1) | DK3092256T3 (enExample) |
| ES (1) | ES2916873T3 (enExample) |
| IL (3) | IL246679A0 (enExample) |
| SG (3) | SG11201605296SA (enExample) |
| TW (3) | TWI691338B (enExample) |
| WO (3) | WO2015103987A1 (enExample) |
Families Citing this family (57)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
| CN112587671A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| CA2936375A1 (en) | 2014-01-10 | 2015-07-16 | Shanghai Birdie Biotech, Inc. | Compounds and compositions for treating her2 positive tumors |
| FI4001311T3 (fi) | 2014-07-09 | 2026-01-27 | Birdie Biopharmaceuticals Inc | Pd-l1/pd-1-vasta-aineiden yhdistelmiä kasvaimien hoitoon |
| CN105440135A (zh) | 2014-09-01 | 2016-03-30 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| AU2016322813B2 (en) | 2015-09-14 | 2021-04-01 | Pfizer Inc. | Novel imidazo (4,5-c) quinoline and imidazo (4,5-c)(1,5) naphthyridine derivatives as LRRK2 inhibitors |
| MA44334A (fr) * | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| CA3007311A1 (en) * | 2015-12-07 | 2017-06-15 | Opi Vi - Ip Holdco Llc | Compositions of antibody construct-agonist conjugates and methods of use thereof |
| CN106943598A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-her2组合 |
| CN115252792A (zh) * | 2016-01-07 | 2022-11-01 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| MD3423105T2 (ro) | 2016-03-02 | 2021-10-31 | Eisai R&D Man Co Ltd | Conjugați anticorp-medicament pe bază de eribulină și metode de utilizare |
| WO2018009916A1 (en) | 2016-07-07 | 2018-01-11 | The Board Of Trustees Of The Leland Stanford Junior University | Antibody adjuvant conjugates |
| CN107773762B (zh) * | 2016-08-31 | 2021-06-15 | 上海干云生物科技有限公司 | 基于pd-l1抗体偶联化疗药物的adc及其制备方法和应用 |
| KR20190075921A (ko) | 2016-10-28 | 2019-07-01 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| CA3042583A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| JP2020511501A (ja) * | 2016-12-13 | 2020-04-16 | ボルト バイオセラピューティクス、インコーポレーテッド | 抗体アジュバント複合体 |
| EP4218824A3 (en) * | 2017-04-14 | 2023-08-09 | Bolt Biotherapeutics, Inc. | Immunoconjugate synthesis method |
| CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| CN110769827A (zh) * | 2017-06-23 | 2020-02-07 | 博笛生物科技有限公司 | 药物组合物 |
| AU2018295540B2 (en) | 2017-07-04 | 2023-05-25 | Intocell, Inc. | Compounds comprising cleavable linker and uses thereof |
| US10618896B2 (en) | 2017-08-22 | 2020-04-14 | Dynavax Technologies Corporation | Alkyl chain modified imidazoquinoline TLR7/8 agonist compounds and uses thereof |
| EP3706775A4 (en) | 2017-11-06 | 2021-09-01 | Trillium Therapeutics Inc. | BLOCKING OF CD47 ASSOCIATED WITH RADIATION THERAPY |
| US10722591B2 (en) | 2017-11-14 | 2020-07-28 | Dynavax Technologies Corporation | Cleavable conjugates of TLR7/8 agonist compounds, methods for preparation, and uses thereof |
| KR102436923B1 (ko) * | 2018-01-26 | 2022-08-26 | 주식회사 엘지화학 | 광 감응기를 포함하는 블록 공중합체 |
| EP3763699A4 (en) * | 2018-03-03 | 2021-12-08 | The University of Tokyo | PRODRUG CANCER MEDICINE WITH CANCER SPECIFIC ENZYMATIC ACTIVITY |
| WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
| TWI672637B (zh) * | 2018-05-03 | 2019-09-21 | 長庚醫療財團法人林口長庚紀念醫院 | 自體免疫抗體免疫螢光影像型態識別方法 |
| JP7423085B2 (ja) * | 2018-05-25 | 2024-01-29 | プリミューン・セラピューティクス・インコーポレイテッド | Ｔｌｒ７アゴニスト |
| CN109134654B (zh) * | 2018-08-02 | 2021-08-03 | 广东药科大学 | 一种靶向egfr二聚化界面的单链抗体及其应用 |
| AU2019340366B2 (en) | 2018-09-10 | 2025-01-02 | Mirati Therapeutics, Inc. | Combination therapies |
| FR3085952B1 (fr) | 2018-09-17 | 2020-10-30 | Centre Nat Rech Scient | Conjugue anticorps-medicament comprenant des derives de quinoline |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CA3124758A1 (en) * | 2019-01-03 | 2020-07-09 | Intocell, Inc. | Compounds comprising cleavable linker and uses thereof |
| EP3906063A4 (en) * | 2019-01-03 | 2023-03-01 | Intocell, Inc. | COMPOUNDS COMPRISING A CLEAVABLE LINKER AND THEIR USES |
| MX2021009644A (es) * | 2019-02-12 | 2021-09-08 | Ambrx Inc | Composiciones que contienen, metodos y usos de conjugados de anticuerpo-agonista de tlr. |
| WO2020190731A1 (en) * | 2019-03-15 | 2020-09-24 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting her2 |
| AU2020241686A1 (en) | 2019-03-15 | 2021-11-04 | Bolt Biotherapeutics, Inc. | Immunoconjugates targeting HER2 |
| JP7735291B2 (ja) | 2020-02-21 | 2025-09-08 | エーアールエス ファーマシューティカルズ、インコーポレイテッド | ネクチン－４抗体コンジュゲートおよびその使用 |
| KR20230047361A (ko) | 2020-07-01 | 2023-04-07 | 아르스 파마슈티컬스 인크. | 항-asgr1 항체 접합체 및 이의 용도 |
| CN116056725A (zh) * | 2020-08-04 | 2023-05-02 | 蛋白科技先鋒 | 活性位点暂时灭活的功能性药物与Toll样受体7或8激动剂的缀合物及其用途 |
| AU2021332350A1 (en) * | 2020-08-26 | 2023-03-16 | Birdie Pharmaceuticals, Inc. | Cancer treatment with TLR agonist |
| CA3192236A1 (en) | 2020-09-10 | 2022-03-17 | Tony Lahoutte | Antibody fragment against fap |
| US20230373997A1 (en) * | 2020-10-08 | 2023-11-23 | Icahn School Of Medicine At Mount Sinai | Imdq-peg-chol adjuvant and uses thereof |
| IL303350A (en) | 2020-12-04 | 2023-08-01 | Macrogenics Inc | Pharmaceutical compositions of a her2/neu antibody and use of the same |
| WO2022120014A1 (en) * | 2020-12-04 | 2022-06-09 | Macrogenics, Inc. | Pharmaceutical compositions of a her2/neu antibody and use of the same |
| KR20230154229A (ko) * | 2021-03-02 | 2023-11-07 | 더 리서치 파운데이션 포 더 스테이트 유니버시티 오브 뉴욕 | 암 및/또는 감염성 질병의 치료를 위한 tlr7 및 tlr8 작용제 |
| US20250064922A1 (en) | 2021-08-30 | 2025-02-27 | Toray Industries, Inc. | Composition for enhancing immunogenicity |
| JPWO2023032892A1 (enExample) | 2021-08-30 | 2023-03-09 | ||
| US20240366739A1 (en) | 2021-09-16 | 2024-11-07 | Toray Industries, Inc. | Medicament for treatment and/or prevention of cancer |
| US20250332265A1 (en) | 2021-11-09 | 2025-10-30 | Case Western Reserve University | Psma targeted conjugate compounds and uses thereof |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
| AU2023403422A1 (en) | 2022-11-30 | 2025-07-17 | Regeneron Pharmaceuticals, Inc. | Tlr7 agonists and antibody-drug-conjugates thereof |
| WO2025015586A1 (en) * | 2023-07-20 | 2025-01-23 | Canwell Biotech Limited | Drug conjugates of imidazoquinoline amine derivatives, compositions and methods thereof |
| WO2025240397A1 (en) * | 2024-05-14 | 2025-11-20 | The Research Foundation For The State University Of New York | Tlr7 and tlr8 agonists and antibody-drug congjugates for the treatment of cancer |
| US20250367314A1 (en) * | 2024-05-31 | 2025-12-04 | Du-Shieng Chien | Linker-payload, an antibody-drug conjugate made thereby and uses thereof |
Family Cites Families (183)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1271477A (en) | 1983-11-18 | 1990-07-10 | John F. Gerster | 1h-imidazo[4,5-c]quinolin-4-amines |
| IL73534A (en) | 1983-11-18 | 1990-12-23 | Riker Laboratories Inc | 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds |
| US4880935A (en) | 1986-07-11 | 1989-11-14 | Icrf (Patents) Limited | Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| IL89220A (en) | 1988-02-11 | 1994-02-27 | Bristol Myers Squibb Co | Anthracycline immunoconjugates, their production and pharmaceutical compositions containing them |
| DE68913658T3 (de) | 1988-11-11 | 2005-07-21 | Stratagene, La Jolla | Klonierung von Immunglobulin Sequenzen aus den variablen Domänen |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US6399754B1 (en) | 1991-12-24 | 2002-06-04 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides |
| US6005087A (en) | 1995-06-06 | 1999-12-21 | Isis Pharmaceuticals, Inc. | 2'-modified oligonucleotides |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| US5496938A (en) | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
| US5763177A (en) | 1990-06-11 | 1998-06-09 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
| US5789163A (en) | 1990-06-11 | 1998-08-04 | Nexstar Pharmaceuticals, Inc. | Enzyme linked oligonucleotide assays (ELONAS) |
| US5874218A (en) | 1990-06-11 | 1999-02-23 | Nexstar Pharmaceuticals, Inc. | Method for detecting a target compound in a substance using a nucleic acid ligand |
| US5567588A (en) | 1990-06-11 | 1996-10-22 | University Research Corporation | Systematic evolution of ligands by exponential enrichment: Solution SELEX |
| US6465189B1 (en) | 1990-06-11 | 2002-10-15 | Gilead Sciences, Inc. | Systematic evolution of ligands by exponential enrichment: blended selex |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| US5475096A (en) | 1990-06-11 | 1995-12-12 | University Research Corporation | Nucleic acid ligands |
| US6716580B2 (en) | 1990-06-11 | 2004-04-06 | Somalogic, Inc. | Method for the automated generation of nucleic acid ligands |
| US6001577A (en) | 1998-06-08 | 1999-12-14 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex |
| US6280932B1 (en) | 1990-06-11 | 2001-08-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands to lectins |
| US5660985A (en) | 1990-06-11 | 1997-08-26 | Nexstar Pharmaceuticals, Inc. | High affinity nucleic acid ligands containing modified nucleotides |
| US5853984A (en) | 1990-06-11 | 1998-12-29 | Nexstar Pharmaceuticals, Inc. | Use of nucleic acid ligands in flow cytometry |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| US5389640A (en) | 1991-03-01 | 1995-02-14 | Minnesota Mining And Manufacturing Company | 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| US5226575A (en) | 1991-11-21 | 1993-07-13 | Scott Faust | Pneumatic mortar dispenser with flex release |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| ATE503496T1 (de) | 1992-02-06 | 2011-04-15 | Novartis Vaccines & Diagnostic | Biosynthetisches bindeprotein für tumormarker |
| US6608201B2 (en) | 1992-08-28 | 2003-08-19 | 3M Innovative Properties Company | Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines |
| US6214345B1 (en) | 1993-05-14 | 2001-04-10 | Bristol-Myers Squibb Co. | Lysosomal enzyme-cleavable antitumor drug conjugates |
| US5352784A (en) | 1993-07-15 | 1994-10-04 | Minnesota Mining And Manufacturing Company | Fused cycloalkylimidazopyridines |
| US6458539B1 (en) | 1993-09-17 | 2002-10-01 | Somalogic, Inc. | Photoselection of nucleic acid ligands |
| US5798340A (en) | 1993-09-17 | 1998-08-25 | Gilead Sciences, Inc. | Nucleotide analogs |
| US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
| US5482936A (en) | 1995-01-12 | 1996-01-09 | Minnesota Mining And Manufacturing Company | Imidazo[4,5-C]quinoline amines |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5843732A (en) | 1995-06-06 | 1998-12-01 | Nexstar Pharmaceuticals, Inc. | Method and apparatus for determining consensus secondary structures for nucleic acid sequences |
| JP2000503639A (ja) | 1995-12-22 | 2000-03-28 | ブリストル―マイヤーズ スクイブ カンパニー | 分枝ヒドラゾンのリンカー類 |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| ATE228529T1 (de) | 1996-08-30 | 2002-12-15 | Jens Peter Fuerste | Spiegelselektion und spiegelevolution von nucleinsäuren |
| US6127533A (en) | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
| UA67760C2 (uk) | 1997-12-11 | 2004-07-15 | Міннесота Майнінг Енд Мануфакчурінг Компані | Імідазонафтиридин та тетрагідроімідазонафтиридин, фармацевтична композиція, спосіб індукування біосинтезу цитокінів та спосіб лікування вірусної інфекції, проміжні сполуки |
| US6242246B1 (en) | 1997-12-15 | 2001-06-05 | Somalogic, Inc. | Nucleic acid ligand diagnostic Biochip |
| US6110929A (en) | 1998-07-28 | 2000-08-29 | 3M Innovative Properties Company | Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof |
| US6403779B1 (en) | 1999-01-08 | 2002-06-11 | Isis Pharmaceuticals, Inc. | Regioselective synthesis of 2′-O-modified nucleosides |
| US20030054360A1 (en) | 1999-01-19 | 2003-03-20 | Larry Gold | Method and apparatus for the automated generation of nucleic acid ligands |
| US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| US6451810B1 (en) | 1999-06-10 | 2002-09-17 | 3M Innovative Properties Company | Amide substituted imidazoquinolines |
| CN100482281C (zh) | 1999-06-25 | 2009-04-29 | 基因技术股份有限公司 | 抗ErbB抗体-类美坦素偶联物在制备药物中的应用 |
| US6506887B1 (en) | 1999-07-29 | 2003-01-14 | Somalogic, Incorporated | Conditional-selex |
| US6635677B2 (en) | 1999-08-13 | 2003-10-21 | Case Western Reserve University | Methoxyamine combinations in the treatment of cancer |
| US6376669B1 (en) | 1999-11-05 | 2002-04-23 | 3M Innovative Properties Company | Dye labeled imidazoquinoline compounds |
| US8202979B2 (en) | 2002-02-20 | 2012-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid |
| US20050032733A1 (en) | 2001-05-18 | 2005-02-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA) |
| US20050020525A1 (en) | 2002-02-20 | 2005-01-27 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| US7097840B2 (en) | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| DE20014503U1 (de) | 2000-08-22 | 2001-01-11 | Siemens AG, 80333 München | Fertigungsstraßenabschnitt |
| US6376190B1 (en) | 2000-09-22 | 2002-04-23 | Somalogic, Inc. | Modified SELEX processes without purified protein |
| UA74593C2 (en) | 2000-12-08 | 2006-01-16 | 3M Innovative Properties Co | Substituted imidazopyridines |
| US6664264B2 (en) | 2000-12-08 | 2003-12-16 | 3M Innovative Properties Company | Thioether substituted imidazoquinolines |
| WO2006091720A2 (en) | 2000-12-08 | 2006-08-31 | 3M Innovative Properties Company | Compositions and methods for targeted delivery of immune response modifiers |
| UA75622C2 (en) | 2000-12-08 | 2006-05-15 | 3M Innovative Properties Co | Aryl ether substituted imidazoquinolines, pharmaceutical composition based thereon |
| US20060057651A1 (en) | 2000-12-08 | 2006-03-16 | Bowdish Katherine S | Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof |
| US20030175950A1 (en) | 2001-05-29 | 2003-09-18 | Mcswiggen James A. | RNA interference mediated inhibition of HIV gene expression using short interfering RNA |
| ATE452655T1 (de) | 2001-06-10 | 2010-01-15 | Noxxon Pharma Ag | Verwendung von l-polynukleotiden zur diagnostischen bilderzeugung |
| AU2775402A (en) | 2001-06-29 | 2003-01-02 | Medimolecular Pty Ltd | Nucleic acid ligands to complex targets |
| US20030139364A1 (en) | 2001-10-12 | 2003-07-24 | University Of Iowa Research Foundation | Methods and products for enhancing immune responses using imidazoquinoline compounds |
| ATE416771T1 (de) | 2001-11-16 | 2008-12-15 | 3M Innovative Properties Co | N-ä4-(4-amino-2-ethyl-1h-imidazoä4,5-cüchinolin 1-yl)butylümethanesulfonamide, diese enthaltende pharmazeutische zusammensetzung und deren verwendung |
| HRP20040541A2 (en) | 2001-11-27 | 2004-10-31 | Anadys Pharmaceuticals | 3- -D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIMIDINE NUCLEOSIDES AND USES THEREOF |
| AU2002360733A1 (en) | 2001-12-31 | 2003-07-24 | Guilford Pharmaceuticals Inc. | SUBSTITUTED 4,9-DIHYDROCYCLOPENTA(imn)PHENANTHRIDINE-5-ONES DERIVATIVES THEREOF AND THEIR USES |
| IL149820A0 (en) | 2002-05-23 | 2002-11-10 | Curetech Ltd | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency |
| US20040092470A1 (en) | 2002-06-18 | 2004-05-13 | Leonard Sherry A. | Dry powder oligonucleotide formualtion, preparation and its uses |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| CA2802205C (en) | 2002-07-31 | 2016-01-19 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| EP1413316A1 (en) | 2002-09-27 | 2004-04-28 | Bruno Robert | Bifunctional conjugates or fusion proteins |
| WO2004058759A1 (en) | 2002-12-20 | 2004-07-15 | 3M Innovative Properties Company | Aryl / hetaryl substituted imidazoquinolines |
| ES2367430T3 (es) | 2002-12-23 | 2011-11-03 | Wyeth Llc | Anticuerpos contra pd-1 y sus usos. |
| US20050036951A1 (en) | 2003-01-09 | 2005-02-17 | Arizeke Pharmaceuticals, Inc. | Methods of treating lung diseases |
| US9259459B2 (en) | 2003-01-31 | 2016-02-16 | Celldex Therapeutics Inc. | Antibody vaccine conjugates and uses therefor |
| JP2006517974A (ja) | 2003-02-13 | 2006-08-03 | スリーエム イノベイティブ プロパティズ カンパニー | Ｉｒｍ化合物およびトル様受容体８に関する方法および組成物 |
| EP1594542B1 (en) | 2003-02-20 | 2010-06-30 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer |
| WO2005025583A2 (en) | 2003-09-05 | 2005-03-24 | Anadys Pharmaceuticals, Inc. | Tlr7 ligands for the treatment of hepatitis c |
| EP1673087B1 (en) | 2003-10-03 | 2015-05-13 | 3M Innovative Properties Company | Alkoxy substituted imidazoquinolines |
| BRPI0414867A (pt) | 2003-10-03 | 2006-11-21 | 3M Innovative Properties Co | pirazolopiridinas e seus análogos |
| RU2426734C2 (ru) | 2003-10-03 | 2011-08-20 | Зм Инновейтив Пропертиз Компани | Пиразолопиридины и их аналоги |
| CA2542099A1 (en) | 2003-10-11 | 2005-04-21 | Inex Pharmaceuticals Corporation | Methods and compositions for enhancing innate immunity and antibody dependent cellular cytotoxicity |
| ITMI20032121A1 (it) | 2003-11-04 | 2005-05-05 | Dinamite Dipharma Spa In Forma Abbr Eviata Dipharm | Procedimento per la preparazione di imiquimod e suoi intermedi |
| CN103394083B (zh) * | 2003-11-06 | 2017-07-18 | 西雅图基因公司 | 能够与配体偶联的单甲基缬氨酸化合物 |
| WO2005067500A2 (en) | 2003-12-30 | 2005-07-28 | 3M Innovative Properties Company | Enhancement of immune responses |
| EP1728793B1 (en) | 2004-03-26 | 2016-02-03 | Sumitomo Dainippon Pharma Co., Ltd. | 9-substituted 8-oxoadenine compound |
| JP2008506683A (ja) | 2004-07-18 | 2008-03-06 | コーリー ファーマシューティカル グループ， リミテッド | 先天免疫応答を誘導するための方法および組成物 |
| SI1791565T1 (sl) * | 2004-09-23 | 2016-08-31 | Genentech, Inc. | Cisteinsko konstruirana protitelesa in konjugati |
| EP1809671B1 (en) | 2004-11-09 | 2014-07-16 | University Of Southern California | CpG/antibody conjugate against cancer |
| EP1830876B1 (en) * | 2004-12-30 | 2015-04-08 | Meda AB | Use of imiquimod for the treatment of cutaneous metastases derived from a breast cancer tumor |
| AU2006216629A1 (en) | 2005-02-24 | 2006-08-31 | Janssen Pharmaceutica N.V. | Novel quinoline derivatives as potassium ion channel openers |
| WO2006108627A1 (en) | 2005-04-14 | 2006-10-19 | Merck Patent Gmbh | Anti-egfr antibody therapy based on an increased copy number of the egfr gene in tumor tissues |
| EP1871418B1 (en) | 2005-04-19 | 2014-03-19 | Seattle Genetics, Inc. | Humanized anti-cd70 binding agents and uses thereof |
| CN101355928B (zh) | 2005-04-26 | 2013-05-22 | 卫材R&D管理株式会社 | 用于癌症免疫疗法的组合物和方法 |
| CN104293780A (zh) | 2005-05-04 | 2015-01-21 | 诺松制药股份公司 | 结合hmga的核酸 |
| AU2006244885B2 (en) | 2005-05-09 | 2011-03-31 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
| AU2006265108C1 (en) | 2005-07-01 | 2013-01-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (PD-L1) |
| WO2007008848A2 (en) | 2005-07-07 | 2007-01-18 | Seattle Genetics, Inc. | Monomethylvaline compounds having phenylalanine carboxy modifications at the c-terminus |
| TW201402124A (zh) | 2005-08-19 | 2014-01-16 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之８-經取代苯并氮雜呯 |
| TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯 |
| JP2009506790A (ja) | 2005-09-07 | 2009-02-19 | メディミューン，エルエルシー | 毒素とコンジュゲートしたｅｐｈ受容体抗体 |
| ZA200803029B (en) | 2005-09-09 | 2009-02-25 | Coley Pharm Group Inc | Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods |
| EP1940470B1 (en) * | 2005-09-26 | 2013-04-17 | Medarex, Inc. | Antibody-drug conjugates and their use |
| WO2007100634A2 (en) | 2006-02-22 | 2007-09-07 | 3M Innovative Properties Company | Immune response modifier conjugates |
| WO2007103048A2 (en) | 2006-03-01 | 2007-09-13 | Regents Of The University Of Colorado | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity |
| US20080031887A1 (en) | 2006-06-30 | 2008-02-07 | Joseph Lustgarten | Conjugates for inducing targeted immune responses and methods of making and using same |
| EP2041135A4 (en) | 2006-07-05 | 2010-12-01 | Astrazeneca Ab | As TLR7 MODULATORS, 8-OXOADENINE DERIVATIVES WORK |
| CA2667019C (en) | 2006-10-27 | 2016-03-29 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
| PL2125779T3 (pl) | 2006-12-21 | 2016-11-30 | Polimorfy antagonisty receptora mglur5 | |
| US20080149123A1 (en) * | 2006-12-22 | 2008-06-26 | Mckay William D | Particulate material dispensing hairbrush with combination bristles |
| US20080261913A1 (en) | 2006-12-28 | 2008-10-23 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of liver disorders |
| TWI422594B (zh) | 2007-02-02 | 2014-01-11 | Baylor Res Inst | 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑 |
| EP2125007B9 (en) | 2007-02-07 | 2014-04-16 | The Regents of The University of California | Conjugates of synthetic tlr agonists and uses therefor |
| JP5394246B2 (ja) * | 2007-03-30 | 2014-01-22 | ジェネンテック， インコーポレイテッド | 抗体及びイムノコンジュゲートとこれらの使用方法 |
| DK2155743T3 (da) | 2007-05-08 | 2012-11-05 | Astrazeneca Ab | Imidazoquinoliner med immunmodulerende egenskaber |
| CA2695385A1 (en) | 2007-07-31 | 2009-02-05 | Atul Bedi | Polypeptide-nucleic acid conjugate for immunoprophylaxis or immunotherapy for neoplastic or infectious disorders |
| JP6035009B2 (ja) | 2007-08-22 | 2016-11-30 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用 |
| EA023175B1 (ru) | 2007-09-28 | 2016-05-31 | Бинд Терапьютикс, Инк. | Таргетирование раковых клеток с использованием наночастиц |
| EA018579B1 (ru) | 2008-01-15 | 2013-09-30 | Меда Аб | Способ лечения полипов/полипоза и предраковых изменений толстого кишечника |
| AU2009207287B2 (en) | 2008-01-25 | 2014-09-11 | Gavish-Galilee Bio Applications Ltd | Targeting of innate immune response to tumor site |
| CN102088974A (zh) * | 2008-02-07 | 2011-06-08 | 加利福尼亚大学校务委员会 | 用tlr7活化剂对膀胱疾病的治疗 |
| NZ621433A (en) | 2008-03-18 | 2015-10-30 | Genentech Inc | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| EP2316032A1 (en) | 2008-08-20 | 2011-05-04 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for predicting the response to anti-cancer treatment with an agonist of tlr7 or an agonist of tlr8 |
| PL2342226T3 (pl) | 2008-09-26 | 2017-01-31 | Dana-Farber Cancer Institute, Inc. | Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania |
| US8895702B2 (en) | 2008-12-08 | 2014-11-25 | City Of Hope | Development of masked therapeutic antibodies to limit off-target effects; application to anti-EGFR antibodies |
| MX2011006152A (es) | 2008-12-09 | 2011-07-28 | Gilead Sciences Inc | Moduladores de receptores tipo toll. |
| US20100189651A1 (en) | 2009-01-12 | 2010-07-29 | Cytomx Therapeutics, Llc | Modified antibody compositions, methods of making and using thereof |
| PT2427485T (pt) | 2009-05-07 | 2017-03-13 | Immunocellular Therapeutics Ltd | Epitopos cd133 |
| WO2010132622A2 (en) | 2009-05-14 | 2010-11-18 | The Regents Of The University Of California | Anticd20-cpg conjugates and methods of treating b cell malignancies |
| US20110077263A1 (en) | 2009-09-29 | 2011-03-31 | University Of Southern California | Methods and Compositions of Toll-Like Receptor (TLR) Agonists |
| WO2011066389A1 (en) | 2009-11-24 | 2011-06-03 | Medimmmune, Limited | Targeted binding agents against b7-h1 |
| WO2011084725A1 (en) | 2009-12-21 | 2011-07-14 | 3M Innovative Properties Company | 4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM 1-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS |
| WO2011084726A1 (en) | 2009-12-21 | 2011-07-14 | 3M Innovative Properties Company | BIS [4-AMINO-2-(ETHOXYMETHYL)-1-(2-HYDROXY-2-METHYLPROPYL)-1H-IMIDAZO[4,5-c]QUINOLIN-5-IUM] 4-[(3-CARBOXYLATO-2-HYDROXYNAPHTHALEN-1-YL)METHYL]-3-HYDROXYNAPHTHALENE-2-CARBOXYLATE COMPOSITIONS AND METHODS |
| ES2608475T3 (es) | 2010-04-13 | 2017-04-11 | Celldex Therapeutics, Inc. | Anticuerpos que se unen a cd27 humana y usos de los mismos |
| PL2575876T3 (pl) | 2010-05-26 | 2018-07-31 | Selecta Biosciences, Inc. | Szczepionki poliwalentne z syntetycznymi nanonośnikami |
| AR082686A1 (es) | 2010-08-13 | 2012-12-26 | Baylor Res Inst | Adyuvantes de vacuna que direccionan a los adyuvantes de anticuerpos directamente hacia las celulas presentadoras de antigenos |
| RU2603467C2 (ru) | 2010-10-01 | 2016-11-27 | Вентиркс Фармасьютикалз, Инк. | Терапевтическое применение агониста tlr и комбинированная терапия |
| CA2818669A1 (en) * | 2010-12-09 | 2012-06-14 | Barbara Klencke | Treatment of her2-positive cancer with paclitaxel and trastuzumab-mcc-dm1 |
| HUE032638T2 (en) | 2011-01-12 | 2017-10-30 | Ventirx Pharmaceuticals Inc | Toll receptor modulator substituted benzoazepines |
| ES2700514T3 (es) | 2011-02-01 | 2019-02-18 | Genmab As | Anticuerpos humanos y conjugados de anticuerpo-fármaco contra CD74 |
| AR085633A1 (es) | 2011-03-08 | 2013-10-16 | Baylor Res Inst | Coadyuvantes basados en anticuerpos que son dirigidos directamente a las celulas presentadoras en antigenos |
| RS57324B1 (sr) | 2011-04-20 | 2018-08-31 | Medimmune Llc | Antitela i drugi molekuli koji vezuju b7-h1 i pd-1 |
| AU2012244549B2 (en) | 2011-04-21 | 2017-04-20 | Origenis Gmbh | Heterocyclic compounds as kinase inhibitors |
| UY34032A (es) | 2011-04-21 | 2012-11-30 | Origenis Gmbh | Nuevos inhibidores de quinasa |
| US8728486B2 (en) | 2011-05-18 | 2014-05-20 | University Of Kansas | Toll-like receptor-7 and -8 modulatory 1H imidazoquinoline derived compounds |
| LT2734551T (lt) | 2011-07-24 | 2018-04-10 | Cure Tech Ltd. | Humanizuotų imunomoduliuojančių monokloninių antikūnų variantai |
| JP6238459B2 (ja) | 2011-08-01 | 2017-11-29 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニストとｍｅｋ阻害剤を使用する癌の治療方法 |
| JP6046716B2 (ja) | 2011-08-11 | 2016-12-21 | ハンツマン・アドバンスド・マテリアルズ・アメリカズ・エルエルシー | ベンゾオキサジン化合物の生産方法 |
| CA2849259A1 (en) | 2011-09-19 | 2013-03-28 | The Johns Hopkins University | Cancer immunotherapy |
| US9241869B2 (en) | 2011-10-25 | 2016-01-26 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
| US10344261B2 (en) | 2011-11-09 | 2019-07-09 | Ascend Biopharmaceuticals Ltd | Immunomodulatory conjugates |
| WO2013166110A1 (en) * | 2012-05-02 | 2013-11-07 | Yale University | Tlr-agonist-conjugated antibody recruiting molecules (tlr_arms) |
| CA3213528A1 (en) | 2012-05-15 | 2013-11-21 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| CN112587671A (zh) | 2012-07-18 | 2021-04-02 | 博笛生物科技有限公司 | 癌症的靶向免疫治疗 |
| US9845356B2 (en) | 2012-08-03 | 2017-12-19 | Dana-Farber Cancer Institute, Inc. | Single agent anti-PD-L1 and PD-L2 dual binding antibodies and methods of use |
| SG11201501286PA (en) | 2012-08-23 | 2015-05-28 | Agensys Inc | Antibody drug conjugates (adc) that bind to 158p1d7 proteins |
| US10000482B2 (en) | 2012-10-19 | 2018-06-19 | Origenis Gmbh | Kinase inhibitors |
| WO2014060112A1 (en) | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Pyrazolo[4,3-d]pyrimidines as kinase inhibitors |
| EP2787005A1 (en) | 2013-04-02 | 2014-10-08 | Activartis Biotech GmbH | Targeted cancer immune therapy |
| BR112016014410A2 (pt) | 2013-12-20 | 2018-02-20 | The Broad Institute Inc. | terapia de combinação com vacina de neoantígeno |
| CA2936375A1 (en) | 2014-01-10 | 2015-07-16 | Shanghai Birdie Biotech, Inc. | Compounds and compositions for treating her2 positive tumors |
| EP3160453A1 (en) | 2014-06-25 | 2017-05-03 | Selecta Biosciences, Inc. | Methods and compositions for treatment with synthetic nanocarriers and immune checkpoint inhibitors |
| FI4001311T3 (fi) | 2014-07-09 | 2026-01-27 | Birdie Biopharmaceuticals Inc | Pd-l1/pd-1-vasta-aineiden yhdistelmiä kasvaimien hoitoon |
| CN105233291A (zh) | 2014-07-09 | 2016-01-13 | 博笛生物科技有限公司 | 用于治疗癌症的联合治疗组合物和联合治疗方法 |
| CN105440135A (zh) | 2014-09-01 | 2016-03-30 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-pd-l1结合物 |
| CN105732635A (zh) | 2014-12-29 | 2016-07-06 | 南京明德新药研发股份有限公司 | 一类Toll样受体7激动剂 |
| DK3345907T3 (da) | 2015-09-01 | 2020-06-22 | Taiho Pharmaceutical Co Ltd | Pyrazolo[3,4-d]pyrimidinforbindelser eller salte deraf |
| US10821127B2 (en) | 2015-11-09 | 2020-11-03 | Shaperon Inc. | Composition for inhibiting myeloid-derived suppressor cells comprising decitabine or its pharmaceutically acceptable salt as active ingredient |
| CN106943596A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-cd20组合 |
| CN115252792A (zh) | 2016-01-07 | 2022-11-01 | 博笛生物科技有限公司 | 用于治疗肿瘤的抗-egfr组合 |
| CN106943598A (zh) | 2016-01-07 | 2017-07-14 | 博笛生物科技（北京）有限公司 | 用于治疗肿瘤的抗-her2组合 |
| CN108794467A (zh) | 2017-04-27 | 2018-11-13 | 博笛生物科技有限公司 | 2-氨基-喹啉衍生物 |
| CN110769827A (zh) | 2017-06-23 | 2020-02-07 | 博笛生物科技有限公司 | 药物组合物 |
| CN113164460A (zh) | 2018-09-07 | 2021-07-23 | 博笛生物科技有限公司 | 咪唑喹啉化合物及其应用 |
| EP3902532A4 (en) | 2018-12-26 | 2022-08-24 | Birdie Biopharmaceuticals, Inc. | Immune modulatory combinations and methods for treating cancers |
| JP2022525216A (ja) | 2019-03-15 | 2022-05-11 | バーディー バイオファーマシューティカルズ インコーポレイテッド | 癌の治療のための免疫調節組成物および方法 |
| AU2021332350A1 (en) | 2020-08-26 | 2023-03-16 | Birdie Pharmaceuticals, Inc. | Cancer treatment with TLR agonist |
-
2015
- 2015-01-08 CA CA2936375A patent/CA2936375A1/en not_active Abandoned
- 2015-01-08 EP EP15735519.9A patent/EP3092255A4/en not_active Withdrawn
- 2015-01-08 WO PCT/CN2015/070377 patent/WO2015103987A1/en not_active Ceased
- 2015-01-08 SG SG11201605296SA patent/SG11201605296SA/en unknown
- 2015-01-08 CA CA2936377A patent/CA2936377A1/en not_active Abandoned
- 2015-01-08 US US15/110,679 patent/US20170028079A1/en not_active Abandoned
- 2015-01-08 WO PCT/CN2015/070379 patent/WO2015103989A1/en not_active Ceased
- 2015-01-08 EP EP15735122.2A patent/EP3092254A4/en not_active Withdrawn
- 2015-01-08 WO PCT/CN2015/070380 patent/WO2015103990A1/en not_active Ceased
- 2015-01-08 CN CN201580004171.4A patent/CN105899538A/zh active Pending
- 2015-01-08 AU AU2015205755A patent/AU2015205755C1/en not_active Ceased
- 2015-01-08 JP JP2016545803A patent/JP6957154B2/ja not_active Expired - Fee Related
- 2015-01-08 JP JP2016545882A patent/JP2017502068A/ja not_active Withdrawn
- 2015-01-08 SG SG11201605455YA patent/SG11201605455YA/en unknown
- 2015-01-08 EP EP15734849.1A patent/EP3092256B1/en active Active
- 2015-01-08 US US15/110,690 patent/US10548985B2/en active Active
- 2015-01-08 US US15/110,685 patent/US9827329B2/en not_active Expired - Fee Related
- 2015-01-08 EP EP22167502.8A patent/EP4056594A1/en not_active Withdrawn
- 2015-01-08 ES ES15734849T patent/ES2916873T3/es active Active
- 2015-01-08 CN CN201580004172.9A patent/CN105899539B/zh not_active Expired - Fee Related
- 2015-01-08 SG SG11201605449YA patent/SG11201605449YA/en unknown
- 2015-01-08 AU AU2015205756A patent/AU2015205756A1/en not_active Abandoned
- 2015-01-08 DK DK15734849.1T patent/DK3092256T3/da active
- 2015-01-08 CN CN202210215606.1A patent/CN114716555A/zh active Pending
- 2015-01-08 CN CN201580004156.XA patent/CN105899537A/zh active Pending
- 2015-01-08 AU AU2015205753A patent/AU2015205753A1/en not_active Abandoned
- 2015-01-08 CN CN202210258366.3A patent/CN114671954A/zh active Pending
- 2015-01-08 JP JP2016545802A patent/JP2017503803A/ja not_active Withdrawn
- 2015-01-08 CA CA2936376A patent/CA2936376A1/en active Pending
- 2015-01-08 CN CN202110943239.2A patent/CN113633783A/zh active Pending
- 2015-01-09 TW TW104100853A patent/TWI691338B/zh not_active IP Right Cessation
- 2015-01-09 TW TW104100854A patent/TWI674904B/zh not_active IP Right Cessation
- 2015-01-09 TW TW104100852A patent/TWI691337B/zh not_active IP Right Cessation
-
2016
- 2016-07-10 IL IL246679A patent/IL246679A0/en unknown
- 2016-07-10 IL IL246680A patent/IL246680A0/en unknown
- 2016-07-10 IL IL246681A patent/IL246681A0/en unknown
-
2017
- 2017-10-25 US US15/793,820 patent/US10328158B2/en active Active
-
2019
- 2019-05-02 US US16/401,797 patent/US10780180B2/en not_active Expired - Fee Related
- 2019-05-02 US US16/401,834 patent/US10744206B2/en not_active Expired - Fee Related
- 2019-12-12 US US16/711,652 patent/US20200155700A1/en not_active Abandoned
-
2020
- 2020-03-19 JP JP2020048941A patent/JP7290332B2/ja active Active
- 2020-05-19 US US16/878,010 patent/US11786604B2/en active Active
- 2020-07-21 US US16/934,803 patent/US11633494B2/en active Active
- 2020-07-28 US US16/940,697 patent/US11633495B2/en active Active
-
2022
- 2022-07-04 JP JP2022107558A patent/JP2022126880A/ja active Pending
-
2023
- 2023-04-17 US US18/135,607 patent/US20230390410A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017502068A5 (enExample) | ||
| JP2017503803A5 (enExample) | ||
| JP2017530187A5 (enExample) | ||
| JP2017507912A5 (enExample) | ||
| JP2017521420A5 (enExample) | ||
| JP2019501195A5 (ja) | 腫瘍を処置するための抗ｅｇｆｒ組み合わせ | |
| JP2019501197A5 (ja) | 腫瘍を処置するための抗ｈｅｒ２組み合わせ | |
| ES2535876T7 (es) | Imidazoles 2-piridil sustituidos como inhibidores terapéuticos de ALK5 y/o ALK4 | |
| JP2006503010A5 (enExample) | ||
| JP2014511893A5 (enExample) | ||
| CA2925257C (en) | 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes | |
| JP2010509356A5 (enExample) | ||
| JP2017511360A5 (enExample) | ||
| JP2007529421A5 (enExample) | ||
| JP2017521421A5 (ja) | 癌を治療するための併用療法組成物 | |
| JP2017524668A5 (enExample) | ||
| JP2006523193A5 (enExample) | ||
| JP2008526752A5 (enExample) | ||
| JP2016525075A5 (enExample) | ||
| EA036001B1 (ru) | Комбинация эрлотиниба и ингибитора глутаминазы для лечения рака легких | |
| JP2010513523A5 (enExample) | ||
| ME02125B (me) | Inhibitori protein apoptoze (iap) | |
| JP2013522249A (ja) | モルホリニルキナゾリン | |
| JPWO2012144463A1 (ja) | 腫瘍治療剤 | |
| JP2016519685A5 (enExample) |